Posted by Claus Andersen, Partner
What to take from the annual meeting of the Medicon Valley Alliance
On 11th October 2018 Thomas Bjørn and Claus Andersen attended the annual meeting of the Medicon Valley Alliance.
Medicon Valley Alliance is a non-profit membership organization in the Danish-Swedish life science cluster Medicon Valley, which is a part of Greater Copenhagen and southern Sweden. With more than 250 members, who together employ approximately 140.000 people, it represents the region’s universities, hospitals, human life science business, regional governments and service providers.
There were a number of speakers from various players in the Life Sciences Industry, such as the pharmaceutical company Roche, accountants PWC, private equity houses NGT – Partners and Hadean Ventures and NASDAQ. There were also seminars from established Danish pharmaceutical LEO Phama A/S and a younger life sciences company, Immunovia, where CEO Mats Grahn told about their journey from start up to fully grown company.
There were many different points being made during the conference. I think that one of the most interesting points was that the UK is still in the top 10 in terms of export markets for life sciences products from Denmark and Sweden. The interesting development is that much of last years growth take place in China and that the price pressure in the US can now be felt.
Another feature was how life sciences companies are trying to attract investment from private equity and what investors are looking for in such companies. One feature that may surprise many is that the stock exchange in Stockholm is actually one of the stock exchanges in Europe, which has seen the most IPOs in Europe. This is testament to the strength of Scandinavian Life Sciences Sector.
Finally, it was interesting to see how new technology such as AI is used increasingly in the sector.
A number of speakers mentioned Brexit as a factor of uncertainty. Brexit will have a big impact on this sector, and it is one of the areas, where it will have particular importance whether the UK will leave the EU with or without a deal. Given the outcome of last week’s summit, we will have to wait a little longer to be certain as how the UK will leave the EU, and what impact this will have on the Life Science sector.
If you have any questions about Life Sciences, please feel free to contact Claus Andersen on:
020 7842 1462 Email us